Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Arrowhead Pharmaceuticals (ARWR) Change in Cash (2016 - 2025)

Arrowhead Pharmaceuticals' Change in Cash history spans 16 years, with the latest figure at -$25.0 million for Q4 2025.

For Q4 2025, Change in Cash rose 48.67% year-over-year to -$25.0 million; the TTM value through Dec 2025 reached $148.0 million, up 1862.31%, while the annual FY2025 figure was $124.3 million, 1101.89% up from the prior year.
Change in Cash reached -$25.0 million in Q4 2025 per ARWR's latest filing, down from $96.8 million in the prior quarter.
In the past five years, Change in Cash ranged from a high of $232.5 million in Q1 2021 to a low of -$141.5 million in Q3 2021.
Average Change in Cash over 5 years is $2.9 million, with a median of -$27.3 million recorded in 2023.
Peak YoY movement for Change in Cash: plummeted 2434.35% in 2021, then soared 435.71% in 2024.
A 5-year view of Change in Cash shows it stood at -$92.8 million in 2021, then soared by 201.68% to $94.4 million in 2022, then plummeted by 155.88% to -$52.7 million in 2023, then rose by 7.6% to -$48.7 million in 2024, then surged by 48.67% to -$25.0 million in 2025.
Per Business Quant, the three most recent readings for ARWR's Change in Cash are -$25.0 million (Q4 2025), $96.8 million (Q3 2025), and -$56.0 million (Q2 2025).